Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference

The following is a summary of the Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript:Financial Performance:Knight Therapeutics reported Q1 2024 revenues of over $85 million, a growth o

moomoo AIMay 11 15:33 ET · Conference Call

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1

Knight Therapeutics Inc. (GUD.TO) entered Thursday into an exclusive supply and distribution agreement whereby Ironshore Pharmaceuticals & Development, has granted the company the rights to seek regul

MT NewswiresMay 9 11:02 ET

Knight Therapeutics Brief: Entering Into Exclusive Supply and Distribution Agreement With Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America

07:33 AM EDT, 05/09/2024 (MT Newswires) -- Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Cana

MT NewswiresMay 9 07:33 ET

Knight Therapeutics Reports First Quarter 2024 Results

Stockhouse May 9 07:30 ET

Knight Therapeutics Inc. Announces Voting Results From the Annual General Meeting

MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the vot

GlobeNewswireMay 8 18:32 ET

Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City

Stockhouse May 7 07:30 ET